blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3511338

EP3511338 - CARRIER FOR TARGETING NERVE CELLS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  10.05.2021
Database last updated on 07.10.2024
FormerExamination is in progress
Status updated on  17.06.2020
FormerRequest for examination was made
Status updated on  28.02.2020
FormerThe application has been published
Status updated on  14.06.2019
Most recent event   Tooltip10.05.2021Application deemed to be withdrawnpublished on 09.06.2021  [2021/23]
Applicant(s)For all designated states
Ipsen Bioinnovation Limited
102 Park Drive
Milton Park
Abingdon, Oxfordshire OX14 4RY / GB
[2019/29]
Inventor(s)01 / RUMMEL, Andreas
Postfach Bandelstr. 13b
30171 Hannover / DE
02 / WEIL, Tanja
Bardiliweg 8
70186 Stuttgart / DE
03 / GUTCAITS, Aleksandrs
c/o Latvian Institute of Organic Synthesis
21 Aizkraukles St
1006 Riga / LV
 [2019/29]
Representative(s)Gregson, Anna Louise, et al
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2019/29]Gregson, Anna Louise, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London
SE1 9SG / GB
Application number, filing date18212034.526.04.2006
[2019/29]
Priority number, dateDE2005101930226.04.2005         Original published format: DE102005019302
[2019/29]
Filing languageDE
Procedural languageDE
PublicationType: A2 Application without search report 
No.:EP3511338
Date:17.07.2019
Language:DE
[2019/29]
Type: A3 Search report 
No.:EP3511338
Date:21.08.2019
Language:DE
[2019/34]
Search report(s)(Supplementary) European search report - dispatched on:EP19.07.2019
ClassificationIPC:C07K14/195, C07K14/33, A61K38/00
[2019/29]
CPC:
C12N9/52 (EP,US); C07K14/195 (KR); A61K38/00 (EP,KR,US);
A61P17/02 (EP); A61P19/00 (EP); A61P25/00 (EP);
A61P25/04 (EP); A61P25/06 (EP); A61P25/24 (EP);
A61P25/26 (EP); A61P27/02 (EP); C07K14/33 (EP,KR,US);
C12Y304/24069 (EP,US); Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2020/14]
Former [2019/29]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:CARRIER ZUM TARGETING VON NERVENZELLEN[2019/29]
English:CARRIER FOR TARGETING NERVE CELLS[2019/29]
French:PORTEUR DESTINE A CIBLER DES CELLULES NERVEUSES[2019/29]
Examination procedure21.02.2020Amendment by applicant (claims and/or description)
21.02.2020Examination requested  [2020/14]
21.02.2020Date on which the examining division has become responsible
22.06.2020Despatch of a communication from the examining division (Time limit: M06)
12.01.2021Application deemed to be withdrawn, date of legal effect  [2021/23]
03.02.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/23]
Parent application(s)   TooltipEP06724595.1  / EP1874803
EP10011509.6  / EP2345666
EP17154062.8  / EP3181578
Fees paidRenewal fee
22.01.2019Renewal fee patent year 03
22.01.2019Renewal fee patent year 04
22.01.2019Renewal fee patent year 05
22.01.2019Renewal fee patent year 06
22.01.2019Renewal fee patent year 07
22.01.2019Renewal fee patent year 08
22.01.2019Renewal fee patent year 09
22.01.2019Renewal fee patent year 10
22.01.2019Renewal fee patent year 11
22.01.2019Renewal fee patent year 12
22.01.2019Renewal fee patent year 13
15.04.2019Renewal fee patent year 14
31.03.2020Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US2003215468  (WILLIAMS JAMES A [US], et al) [X] 1-15* SEQ ID NOs: 40 and 77;; examples 35,49 *;
 [I]  - WILLEMS A ET AL, "Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins", RESEARCH IN MICROBIOLOGY, ELSEVIER, AMSTERDAM, NL, (1993), vol. 144, no. 7, ISSN 0923-2508, pages 547 - 556, XP002350001 [I] 1-15 * Positions 1255 and 1256 of the amino acid sequence shown in Figure 2. *

DOI:   http://dx.doi.org/10.1016/0923-2508(93)90004-L
 [I]  - RUMMEL A ET AL, "The Hcc-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, (20031215), vol. 51, no. 3, ISSN 0950-382X, pages 631 - 643, XP002363868 [I] 1-15 * figure 1 *

DOI:   http://dx.doi.org/10.1046/j.1365-2958.2003.03872.x
 [I]  - HUTSON R A ET AL, "NUCLEOTIDE SEQUENCE OF THE GENE CODING FOR NON-PROTEOLYTIC CLOSTRIDIUM BOTULINUM TYPE B NEUROTOXIN: COMPARISO WITH OTHER CLOSTRIDIAL NEUROTOXINS", CURRENT MICROBIOLOGY, NEW YORK, NY, US, (1994), vol. 28, no. 2, ISSN 0343-8651, pages 101 - 110, XP001079475 [I] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1007/BF01569055
by applicantWO2006002707
    - SHONE et al., Eur. J. Biochem., (19850000), vol. 151, pages 75 - 82
    - GIMENEZ et al., J. Protein Chem., (19930000), vol. 12, pages 351 - 363
    - HALPEM et al., Curr Top Microbiol Immunol, (19930000), vol. 195, pages 221 - 241
    - LACY et al., Nat. Struct. Biol., (19980000), vol. 5, pages 898 - 902
    - HERREROS et al., Biochem. J., (20000000), vol. 347, pages 199 - 204
    - RUMMEL et al., Mol. Microbiol., (20040000), vol. 51, pages 631 - 643
    - RUMMEL et al., J. Biol. Chem., (20040000), vol. 279, pages 30865 - 70
    - BENECKE et al., Akt. Neurol., (19950000), vol. 22, page 209ff
    - SYCHA et al., J. Neurol., (20040000), vol. 251, pages 19 - 30
    - HABERMANN et al., Naunyn Schmiedeberg's Arch. Pharmacol., (19800000), vol. 311, pages 33 - 40
    - GÖSCHEL H; WOHLFARTH K; FREVERT J; DENGLER R; BIGALKE H, "Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences", Exp. Neurol., (19970900), vol. 147, no. l, pages 96 - 102
    - HALPERN et al., Curr. Top. Microbiol. Immunol., (19950000), vol. 195, pages 221 - 41
    - BINZ et al., Biochemistry, (20020000), vol. 41, no. 6, pages 1717 - 23
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.